Financials Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:07:53 2024-04-16 pm EDT 5-day change 1st Jan Change
86.36 USD +1.39% Intraday chart for Blueprint Medicines Corporation -6.26% -6.30%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,942 6,250 6,302 2,621 5,607 5,343 - -
Enterprise Value (EV) 1 3,458 5,378 5,825 1,815 5,135 5,109 5,210 5,126
P/E ratio -11 x 20.1 x -9.73 x -4.69 x -11 x -15.7 x -33.9 x 203 x
Yield - - - - - - 1.15% 1.15%
Capitalization / Revenue 59.3 x 7.87 x 35 x 12.8 x 22.5 x 13.6 x 8.91 x 6.5 x
EV / Revenue 52 x 6.78 x 32.3 x 8.9 x 20.6 x 13 x 8.69 x 6.23 x
EV / EBITDA -9.71 x 17.1 x -9.17 x -3.45 x -10.8 x -14.9 x -34.1 x 710 x
EV / FCF -11.8 x 14 x -19.3 x -3.55 x -11.3 x -19.9 x -59.4 x 45 x
FCF Yield -8.44% 7.14% -5.18% -28.2% -8.82% -5.02% -1.68% 2.22%
Price to Book 8.5 x 4.41 x 6.53 x 5.1 x 43.2 x 62.8 x 301 x 198 x
Nbr of stocks (in thousands) 49,202 55,731 58,838 59,831 60,790 61,232 - -
Reference price 2 80.11 112.2 107.1 43.81 92.24 87.25 87.25 87.25
Announcement Date 2/13/20 2/17/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 66.51 793.7 180.1 204 249.4 392.9 599.3 822.2
EBITDA 1 -356.1 315.3 -635.5 -525.8 -474.6 -341.9 -152.9 7.221
EBIT 1 -361.3 308.7 -642 -537.5 -486.3 -313 -120.5 74.31
Operating Margin -543.25% 38.89% -356.5% -263.44% -194.99% -79.65% -20.1% 9.04%
Earnings before Tax (EBT) 1 -347.7 314.9 -641.1 -552.3 -506 -342.5 -156.7 16.87
Net income 1 -347.7 313.9 -644.1 -557.5 -507 -340 -160.7 22.53
Net margin -522.75% 39.54% -357.67% -273.24% -203.3% -86.54% -26.81% 2.74%
EPS 2 -7.270 5.590 -11.01 -9.350 -8.370 -5.544 -2.573 0.4300
Free Cash Flow 1 -292 383.9 -301.7 -511.2 -452.9 -256.6 -87.75 114
FCF margin -439.06% 48.36% -167.56% -250.54% -181.61% -65.3% -14.64% 13.86%
FCF Conversion (EBITDA) - 121.76% - - - - - 1,578.29%
FCF Conversion (Net income) - 122.3% - - - - - 505.82%
Dividend per Share 2 - - - - - - 1.000 1.000
Announcement Date 2/13/20 2/17/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 24.19 107 62.73 36.55 65.98 38.78 63.29 57.57 56.57 71.96 81.39 93.07 104.2 115.5 116.3
EBITDA 1 -115.5 -314.5 -104.2 -156.2 -122.7 -142.8 -120.5 -124.4 -126.1 -103.6 -95 -89 -83 -81 -61
EBIT 1 -117.1 -316.1 -105.8 -157.6 -124.3 -149.8 -124.2 -128 -129 -105.1 -94.83 -83.53 -71.1 -59.79 -67.43
Operating Margin -484.11% -295.39% -168.66% -431.33% -188.36% -386.27% -196.26% -222.31% -228.02% -146.07% -116.51% -89.75% -68.2% -51.76% -57.97%
Earnings before Tax (EBT) 1 -117.1 -316.1 -105.8 -156.6 -132.3 -157.6 -129 -132.6 -133.5 -110.9 -101.3 -91.02 -79.92 -70.26 -72.57
Net income 1 -117.2 -318.7 -106 -159.7 -133.2 -158.6 -129.6 -132.8 -133.7 -110.9 -100.9 -90.02 -79.4 -69.69 -72.57
Net margin -484.71% -297.78% -168.97% -437% -201.83% -409.06% -204.72% -230.66% -236.38% -154.14% -124.02% -96.72% -76.17% -60.33% -62.39%
EPS 2 -2.000 -5.400 -1.790 -2.680 -2.230 -2.650 -2.150 -2.190 -2.200 -1.820 -1.647 -1.456 -1.275 -1.102 -1.130
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 10/28/21 2/16/22 5/3/22 8/2/22 11/1/22 2/16/23 5/4/23 8/2/23 10/26/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 484 872 477 806 472 703 554 568
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -292 384 -302 -511 -453 -257 -87.8 114
ROE (net income / shareholders' equity) -78.7% 32.5% -52.8% -75.1% -157% -104% -138% 18.4%
ROA (Net income/ Total Assets) -55.7% - - - - - - -
Assets 1 623.9 - - - - - - -
Book Value Per Share 2 9.420 25.40 16.40 8.580 2.140 1.390 0.2900 0.4400
Cash Flow per Share -5.810 - - - - - - -
Capex 1 14 3.16 3.09 8.92 16.1 12.1 12 11.9
Capex / Sales 21.07% 0.4% 1.72% 4.37% 6.44% 3.08% 2% 1.45%
Announcement Date 2/13/20 2/17/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
87.25 USD
Average target price
97.38 USD
Spread / Average Target
+11.60%
Consensus
  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. Financials Blueprint Medicines Corporation